MIRA Pharmaceuticals, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
MIRA Pharmaceuticals, Inc. (MIRA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 8.02 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- MIRA Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 7.84M shares, a 26.06% increase year-over-year.
- MIRA Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 6.22M shares.
- MIRA Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 7.84M shares, a 42.49% increase from fiscal 2024.
- MIRA Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 5.50M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 8.02M shares 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 7.84M shares 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 7.84M shares 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 5.35M shares 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 5.97M shares 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | 6.22M shares 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 5.50M shares 10-K · filed 2026-03-31 | |||
| 2024-09-30 | 3.64M shares 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |